domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md

@@ -37,6 +37,12 @@ Abridge's clinical outcomes data shows 73% reduction in after-hours documentatio
 
 Epic launched AI Charting in February 2026, creating an immediate commoditization threat to standalone ambient AI platforms. Abridge's response - pivoting to 'more than a scribe' positioning with coding, prior auth automation, and clinical decision support - suggests leadership recognized the documentation beachhead may not be defensible against EHR-native solutions. The timing of this strategic pivot (2025-2026) indicates the scribe adoption success may have a shorter durability window than the 92% adoption figure suggests.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-16*
+
+OpenEvidence (clinical reasoning) and Abridge (documentation) represent two distinct clinical AI beachheads serving different workflows. OpenEvidence's 40%+ daily physician adoption for clinical decision support suggests that point-of-care reasoning AI can achieve adoption rates comparable to documentation AI, challenging the assumption that documentation is uniquely suited for rapid AI adoption.
+
 ---
 
 Relevant Notes:

domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md

@@ -17,6 +17,12 @@ What makes this significant is the adoption speed. Reaching 40% of US physicians
 
 The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveraging its trusted brand and install base. The competitive dynamic -- startup vs incumbent in clinical decision support -- will determine whether AI clinical knowledge becomes a winner-take-all market or fragments.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-16*
+
+OpenEvidence reached 20M clinical consultations/month by January 2026 (2,000%+ YoY growth from 8.5M/month in 2025), achieved 1M consultations in a single day on March 10, 2026, and is now valued at $12B (up from $3.5B, tripling in months). Used across 10,000+ hospitals nationwide. First AI to score 100% on all parts of USMLE.
+
 ---
 
 Relevant Notes:

domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md

@@ -17,6 +17,12 @@ A deeper finding from a Stanford/Harvard study challenges even the "similar accu
 
 The implication for AI deployment strategy: the highest-value clinical AI applications are not diagnostic augmentation but workflow automation (ambient documentation, administrative burden reduction) and safety netting (AI triage catching missed findings). The centaur model may still apply to medicine, but the interaction design must prevent physicians from overriding AI on tasks where AI demonstrably outperforms -- a politically and ethically charged constraint.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-16*
+
+OpenEvidence achieved 100% USMLE score and is now processing 20M physician consultations/month at scale (1M consultations/day milestone), creating the first empirical test case of whether benchmark performance translates to population-level outcomes. However, no peer-reviewed outcomes data has been published despite this unprecedented scale of deployment.
+
 ---
 
 Relevant Notes:

inbox/archive/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md

@@ -7,9 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: [ai-alignment]
 format: company-announcement
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [openevidence, clinical-ai, decision-support, physician-adoption, clinical-decision-support, health-ai, trust]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -68,3 +72,14 @@ This creates a two-track clinical AI story: (1) Abridge/ambient scribes for docu
 PRIMARY CONNECTION: [[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]]
 WHY ARCHIVED: Significant scale update — the existing claim understates 2026 metrics by an order of magnitude. Also: USMLE 100% creates the benchmark vs. outcomes tension in practice, not theory.
 EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim
+
+
+## Key Facts
+- OpenEvidence valued at $12B in January 2026 Series D (up from $6B three months prior, $3.5B in earlier round)
+- 20M clinical consultations/month as of January 2026, up from 8.5M/month in 2025
+- 1M consultations in one day milestone reached March 10, 2026
+- 44% of physicians concerned about accuracy and misinformation risk
+- 19% concerned about lack of physician oversight or explainability
+- Series D: $250M led by Thrive Capital and DST Global
+- Used across 10,000+ hospitals and medical centers nationwide
+- First AI to score 100% on USMLE (all parts)